Use of ultrafiltration/diafiltration for the processing of antisense oligonucleotides

被引:4
|
作者
Gronke, Robert S. [1 ]
Ruanjaikaen, Krisada [2 ]
Delavari, Armin [1 ]
Immel-Brown, Jonas P. [1 ]
Penrod, Joseph C. [3 ]
Lam, Yik [3 ]
Antia, Firoz D. [1 ]
机构
[1] Biogen Inc, Tech Dev, Cambridge, MA 02142 USA
[2] Intellia Therapeut Inc, Tech Operat, Cambridge, MA USA
[3] Biogen Inc, Tech Dev, Durham, NC USA
关键词
membrane polarization; oligonucleotide; ultrafiltration and diafiltration; MEMBRANES; PROTEIN;
D O I
10.1002/btpr.3350
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ultrafiltration/diafiltration (UF/DF) has been the hallmark for concentrating and buffer exchange of protein and peptide-based therapeutics for years. Here we examine the capabilities and limitations of UF/DF membranes to process oligonucleotides using antisense oligonucleotides (ASOs) as a model. Using a 3 kDa UF/DF membrane, oligonucleotides as small as 6 kDa are shown to have low sieving coefficients (<0.008) and thus can be concentrated to high concentrations (= 200 mg/mL) with high yield (= 95%) and low viscosity (<15 centipoise), provided the oligonucleotide is designed not to undergo self-hybridization. In general, the oligonucleotide should be at least twice the reported membrane molecular weight cutoff for robust retention. Regarding diafiltration, results show that a small amount of salt is necessary to maintain adequate flux at concentrations exceeding about 40 mg/mL. Removal of salts along with residual solvents and small molecule process-related impurities can be robust provided they are not positively charged as the interaction with the oligonucleotide can prevent passage through the membrane, even for common divalent cations such as calcium or magnesium. Overall, UF/DF is a valuable tool to utilize in oligonucleotide processing, especially as a final drug substance formulation step that enables a liquid active pharmaceutical ingredient.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] OPTIMIZATION OF ULTRAFILTRATION AND DIAFILTRATION PROCESSES FOR ALBUMIN PRODUCTION
    JAFFRIN, MY
    CHARRIER, JP
    JOURNAL OF MEMBRANE SCIENCE, 1994, 97 : 71 - 81
  • [32] Purification of antisense oligonucleotides
    Deshmukh, RR
    Cole, DL
    Sanghvi, YS
    ANTISENSE TECHNOLOGY, PT A: GENERAL METHODS, METHODS OF DELIVERY, AND RNA STUDIES, 2000, 313 : 203 - 226
  • [33] Pharmacology of antisense oligonucleotides
    Dean, NM
    Cooper, SR
    Shanahan, W
    Taylor, J
    Myers, K
    JOURNAL OF CLINICAL LIGAND ASSAY, 2000, 23 (01): : 43 - 49
  • [34] PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDES
    AGRAWAL, S
    TEMSAMANI, J
    GALBRAITH, W
    TANG, JY
    CLINICAL PHARMACOKINETICS, 1995, 28 (01) : 7 - 16
  • [35] Antisense oligonucleotides in cancer
    Castanotto, Daniela
    Stein, Cy A.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (06) : 584 - 589
  • [36] CHARACTERIZATION OF ANTISENSE OLIGONUCLEOTIDES
    AGRAWAL, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 153 - ANYL
  • [37] Conjugated antisense oligonucleotides
    Manoharan, M
    Tivel, KL
    Condon, TP
    Andrade, LK
    BarberPeoch, I
    Inamati, G
    Shah, S
    Mohan, V
    Graham, MJ
    Bennett, CF
    Crooke, ST
    Cook, PD
    NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9): : 1129 - 1138
  • [38] USE OF OLIGONUCLEOTIDES FOR ANTISENSE EXPERIMENTS IN XENOPUS-LAEVIS OOCYTES
    PRIVES, C
    FOUKAL, D
    METHODS IN CELL BIOLOGY, 1991, 36 : 185 - 210
  • [39] PROSPECTS FOR THE THERAPEUTIC USE OF ANTISENSE OLIGONUCLEOTIDES IN MALIGNANT-LYMPHOMAS
    MAGRATH, IT
    ANNALS OF ONCOLOGY, 1994, 5 : S67 - S70
  • [40] Mechanism of antisense oligonucleotides and their use in gene therapy as a therapeutic agent
    Ruzdijic, S
    Rakic, L
    JUGOSLOVENSKA MEDICINSKA BIOHEMIJA-YUGOSLAV MEDICAL BIOCHEMISTRY, 1998, 17 (03): : 133 - 133